Financial
Latest full-year results from official filings.
FY2026 revenue $36.36bn (+8.4%); operating margin 17.8%; net income $4.80bn.
Balance sheet figures not captured from release.
- Official results release · Medtronic · 24 Apr 2026
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2026 revenue $36.36bn (+8.4%); operating margin 17.8%; net income $4.80bn.
Balance sheet figures not captured from release.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Mar 2026: Medtronic completed the carve-out of its diabetes business, MiniMed Group, which listed separately on Nasdaq.
Data breaches, cyber incidents, regulator action and assurance status.
Apr 2026: Medtronic disclosed a breach of its corporate IT systems after the ShinyHunters group claimed to hold over 9 million records; Medtronic said products, patient safety and manufacturing were not affected. Several proposed class actions followed. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Oct 2025: the FDA classed Medtronic's recall of DLP left heart vent catheters as Class I after 41 complaints that catheters may not hold their shape when bent; Medtronic said no deaths had been reported.
Contract delivery, go-lives, terminations and disputes.
Dec 2025: Medtronic was named one of eight suppliers on NHS Supply Chain's managed services framework lot for angiography equipment and accessories (lot value £399.5m ex VAT across all suppliers).